Evidence map›Paper›PMID 40320531›Full record

ArticlePneumonia (Nathan Qld.)2025

Respiratory dysbiosis as prognostic biomarker of disease severity for adults with community-acquired pneumonia requiring mechanical ventilation.

Loreto Vidaur, Amalur Guridi, Oihana Leizaola, Jokin Marin, Jordi Rello, Cristina Sarasqueta, Ane Sorarrain, Jose María Marimón

Abstract read
In one paragraph

Article in Pneumonia (Nathan Qld.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Loreto VidaurIntensive Care Unit, Donostia University Hospital, Paseo del Dr. Beguiristain S/N, Donostia-San Sebastián, 20014, Spain. LORETO.VIDAURTELLO@osakidetza.eus.
Amalur GuridiIntensive Care Unit, Donostia University Hospital, Paseo del Dr. Beguiristain S/N, Donostia-San Sebastián, 20014, Spain.
Oihana LeizaolaIntensive Care Unit, Donostia University Hospital, Paseo del Dr. Beguiristain S/N, Donostia-San Sebastián, 20014, Spain.
Jokin MarinIntensive Care Unit, Donostia University Hospital, Paseo del Dr. Beguiristain S/N, Donostia-San Sebastián, 20014, Spain.
Jordi RelloCentro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Cristina SarasquetaClinical Epidemiology Department, OSID Donostialdea. Biogipuzkoa, San Sebastian, Spain.
Ane SorarrainMicrobiology Department, Donostia University Hospital, Donostia-San Sebastian, 20014, Spain.
Jose María MarimónBiogipuzkoa, Infectious Diseases Area, Respiratory Infection and Antimicrobial Resistance Group, Osakidetza Basque Health Service, Donostialdea Integrated Health Organization, Microbiology Department, Donostia-San Sebastian, 20014, Spain.

Funding

Instituto de Salud Carlos III FIS17/01463
6 · The paper itself

Abstract

objetivesTo ascertain the role of the lung microbiome in the development of severe pneumonia and its potential as a biomarker for disease progression.

methodsBAL samples from 34 adults with severe community-acquired pneumonia (CAP) (17 viral, 8 viral coinfected with bacteria and 9 bacterial) admitted to the ICU for acute respiratory failure between 2019 and 2021 were collected within the first 48 h of admission to the ICU. The microbiome was characterized via the Ion 16S Metagenomics Kit and the Ion Torrent sequencing platform. Clinical factors, including survival, mechanical ventilation duration, blood biomarkers and organ failure in terms of acute respiratory distress syndrome (ARDS), shock or acute renal failure, were correlated with microbiome characteristics.

resultsThe microbiome diversity in patients with viral pneumonia was significantly greater than that in patients with bacterial or coinfected pneumonia: the Shannon diversity index was 3.75 (Q1-Q3: 2.5-4.1) versus 0.4 (Q1-Q3: 0.2-1.3) and 0.48 (Q1-Q3: 0.3-1.1), respectively (p < 0.05). The microbiome diversity index was associated with severity-of-illness (APACHE II), independent of the etiology of pneumonia (B coefficient -1.845; p < 0.01). Patients with severe viral CAP who developed ARDS had a lower presence of Proteobacteria, and those who were complicated with ventilator-associated pneumonia had a higher prevalence of Acinetobacter at admission. The mortality of patients with bacterial or coinfected pneumonia was 35%. In coinfected patients, the diversity index was associated with the development of shock.

conclusionPatients with severe CAP have low respiratory microbiome diversity, indicating that respiratory microbiome diversity is a potential biomarker of disease severity.

Indexed as

BiomarkersDiversityLung microbiomeSevere community-acquired pneumonia

Identifiers

PMID40320531
PMCPMC12051328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.